MPO: The Rightness Trap in Medtech Organizations
In a recent article for MD+DI, StarFish Medical Commercialization Manager Jason McGee explores how the Rightness Trap Medtech dynamic can quietly erode enterprise value in medical device companies. He argues that many ventures struggle not because of technical gaps, but because leadership becomes too certain at the moment when adaptability is required.
McGee explains that the Rightness Trap limits curiosity and reduces an organization’s ability to respond to market signals. In Medtech, where regulatory complexity and capital intensity shape every decision, this can lead teams to commit too early to strategies that have not been fully validated.
The article highlights how this dynamic shows up at critical inflection points. Leadership teams may commit to a regulatory pathway despite emerging risks, scale operations before demand is proven, or invest heavily in clinical studies before confirming product-market alignment. Each of these decisions can increase capital requirements and reduce flexibility as new information emerges.
McGee also notes that the impact extends beyond individual decisions. Over time, organizations begin to filter out contradictory information, discount external expertise, and favor alignment over constructive dissent. This creates a system that reinforces assumptions rather than testing them against reality.
To address this, the article emphasizes the importance of treating strategy as a set of testable hypotheses. Organizations that continuously validate assumptions, model multiple scenarios, and encourage dissent are better positioned to adapt early and preserve enterprise value.
McGee concludes that the Rightness Trap Medtech challenge is ultimately a commercialization risk. Teams that remain flexible in how they execute, while staying focused on the clinical problem, are more likely to sustain momentum and achieve stronger outcomes.
Explore the full discussion by visiting the complete MD+DI article.
About StarFish Medical
StarFish Medical is a full-service medical device design, development, and specialty manufacturing company headquartered in Victoria, British Columbia, with additional offices in Toronto and Irvine, California.
StarFish Medical works with founder-led start-ups and global enterprises across North America that need to navigate the complexity of building and launching regulated medical technologies. The company combines product design and development with quality and regulatory expertise and manufacturing readiness to help teams move from early concept through commercialization and scaled production. Its experience includes diagnostics, drug delivery, surgical, therapy, and remote devices.
Founded in 1999, StarFish Medical has grown into Canada’s largest full-service medical device design, development, and commercialization partner. It operates as part of StarFish Holdings, which also includes ViVitro Labs, a global cardiovascular device testing company with facilities in Victoria and Marseille, France. In 2020, StarFish Medical led a multi-company Canadian team that updated the Winnipeg Ventilator to address COVID-19 supply chain and operational challenges.
Empowering Medtech Innovation®. www.starfishmedical.com
Contact Patrick Dean, Director of Marketing, for media inquiries.
Related Resources
Jason McGee explores how the Rightness Trap Medtech dynamic can quietly erode enterprise value in medical device companies.
Every MedTech startup begins with a hypothesis, an idea that could transform patient outcomes, simplify delivery of care, or improve how clinicians diagnose and treat patients.
In Medtech, a successful exit isn’t just about having an innovative device, it’s about building a business that potential buyers and investors can clearly see a future in.
Being ready to build is not the same as being ready to scale. Successful market introduction requires manufacturing readiness that evolves alongside market readiness.